BIIB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIIB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current assets includes Cash And Cash Equivalents, Accounts Receivable, Total Inventories, and Other Current Assets. Biogen's total current assets for the quarter that ended in Sep. 2022 was $9,766 Mil.
The historical data trend for Biogen's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.
Biogen's Total Current Assets for the fiscal year that ended in Dec. 2021 is calculated as
Total Current Assets | = | Cash And Cash Equivalents | + | Accounts Receivable | + | Total Inventories | + | Other Current Assets |
= | 3802.5 | + | 1961.7 | + | 1351.5 | + | 740.8 | |
= | 7,857 |
Biogen's Total Current Assets for the quarter that ended in Sep. 2022 is calculated as
Total Current Assets | = | Cash And Cash Equivalents | + | Accounts Receivable | + | Total Inventories | + | Other Current Assets |
= | 4911.1 | + | 1984.2 | + | 1375 | + | 1495.5 | |
= | 9,766 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Biogen (NAS:BIIB) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Biogen's Liquidation Value for the quarter that ended in Sep. 2022 is
Liquidation value | |||||||
= | Cash And Cash Equivalents | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 4911.1 | - | 12087.4 | + | 0.75 * 1984.2 | + | 0.5 * 1375 |
= | -5,001 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Biogen's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Viehbacher | director, officer: President and CEO | C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Nicole Murphy | officer: Head of Pharm Ops and Tech | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Rachid Izzar | officer: Head of Alzheimer's Disease | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Jones William D /ca/ | director | |
Maria C Freire | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Michael R Mcdonnell | officer: EVP, Chief Financial Officer | C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810 |
Alphonse Galdes | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
William A Hawkins | director | MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604 |
Jesus B Mantas | director | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Robin Kramer | officer: VP, Chief Accounting Officer | 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109 |
Daniel Karp | officer: EVP, Corporate Development | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Jeffrey D Capello | officer: EVP & Chief Financial Officer | C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912 |
Chirfi Guindo | officer: EVP Glob. Mkt Acc & Cust Innov | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Ginger Gregory | officer: EVP, Human Resources | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Jean-paul Kress | officer: EVP Pres Int'l & Global Hd GTO | 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
From GuruFocus
By Stock market mentor 01-04-2023
By Stock market mentor 01-05-2023
By Value_Insider 12-19-2022
By PRNewswire 11-30-2022
Other Sources
By Reuters 2023-01-25
By Yahoo Finance 2023-01-26
By Yahoo Finance 2023-01-29
By tipranks.com 2023-01-24
By Zacks 2023-01-30
By Yahoo Finance 2023-01-20
By Yahoo Finance 2023-01-25
By Yahoo Finance 2023-01-30
By Yahoo Finance 2023-01-26
By Yahoo Finance 2023-01-26
By Yahoo Finance 2023-01-29
By Yahoo Finance 2023-01-24
By Bloomberg 2023-01-25
By Zacks 2023-01-27
By Yahoo Finance 2023-01-25
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.